Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Secondary-progressive Multiple Sclerosis Clear all
Completed Phase 1 Interventional

Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis

NCT03493841
View directory record Official record
Conditions
Multiple Sclerosis, Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Alpha Lipoic Acid
Drug
Lead sponsor
Rebecca Spain
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 26, 2026, 4:32 PM EDT
Not yet recruiting Phase 2 Interventional

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

NCT07222956
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions
Remibrutinib (Open Label)
Drug
Lead sponsor
Moein Amin
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Foralumab, Placebo
Drug · Other
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis

NCT06841068
View directory record Official record
Conditions
Multiple Sclerosis, Progressive
Interventions
Amniotic fluid or placental CD117 stem cells
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Active, not recruiting Phase 2 Interventional

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

NCT05122559
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
Emmanuelle Waubant, MD PhD
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Completed No phase listed Observational

Mitochondrial Dysfunction and Disease Progression

NCT02549703
View directory record Official record
Conditions
Clinically Isolated Syndrome, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)

NCT01188811
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
lipoic acid, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 26, 2026, 4:32 PM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 26, 2026, 4:32 PM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Sep 26, 2026, 4:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Active Microglia in Progressive Multiple Sclerosis

NCT02207075
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
[C11]PK-1195 PET scan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients

NCT02253264
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 26, 2026, 4:32 PM EDT
Completed No phase listed Observational

Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis

NCT02330965
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Blood Draw, CSF collection by lumbar puncture (Optional)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
13
States / cities
Berkeley, California • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Early Phase 1 Interventional

Metformin Treatment in Progressive Multiple Sclerosis

NCT05349474
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 26, 2026, 4:32 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis (SPMS)
Interventions
Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

NCT04909502
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD, EHP-101 50 mg BID
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Cullman, Alabama • Fullerton, California • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 26, 2026, 4:32 PM EDT
Completed No phase listed Observational

A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis

NCT06395909
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 26, 2026, 4:32 PM EDT
Recruiting Not applicable Interventional

Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT06276634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Interventions
Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
natalizumab, standard of care
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
12
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 26, 2026, 4:32 PM EDT
Terminated Phase 3 Interventional Results available

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
dimethyl fumarate, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • San Francisco, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 26, 2026, 4:32 PM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627, Placebo
Drug · Other
Lead sponsor
Sundance Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Placebo, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
52
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 26, 2026, 4:32 PM EDT
Completed Phase 1 Interventional

Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS

NCT00813969
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Autologous mesenchymal stem cell transplantation
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Sep 26, 2026, 4:32 PM EDT